Acute Equol Supplementation and Vascular Function in Women With and Without CKD

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Chronic Kidney Diseases, Vascular Function, Women

In brief

The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the acute effect (1-hour, 2-hours, and 3-hours post ingestion) of oral equol supplementation on vascular function in postmenopausal women with and without CKD.

Key facts

Study ID

NCT06128278

Run by

University of Colorado, Denver

People needed

38

Starts

2023-03-07

Expected to finish

2026-12-31

Last updated by the study team

2025-09-30

Who can join

Age: 50 and older, up to 69. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Postmenopausal (50-69 y) women
• Women with CKD including stage 3-4 (eGFR 15-59 ml/min/1.73m2) determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation
• Women without CKD (eGFR >60 ml/min/1.73m2) must be healthy (free from hypertension, kidney disease, CVD, diabetes, and other chronic disease as assessed by self-report, medical history, and screening labs).

You may not qualify if…

• Use of HRT or has used HRT for <6 months prior to enrollment
• Advanced CKD requiring dialysis
• History of kidney transplant
• Use of immunosuppressant medications (unless taking a stable dosage for a quiescent disease)
• Current tobacco or nicotine use or history of use in the last 12 months
• Antioxidant and/or omega-3 fatty acid use within the 2 weeks prior to testing
• Marijuana use within 2 weeks prior to testing
• Consumption of soy and soy-based products 3 days prior to testing
• Uncontrolled hypertension in CKD group (BP>140/90 mmHg)
• Atrial fibrillation
• Active infection or antibiotic therapy
• Hospitalization in the last month

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.